<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01325792</url>
  </required_header>
  <id_info>
    <org_study_id>CS155</org_study_id>
    <nct_id>NCT01325792</nct_id>
  </id_info>
  <brief_title>Open Complex Ventral Incisional Hernia Repair Using Biosynthetic Material for Midline Fascial Closure Reinforcement</brief_title>
  <acronym>COBRA</acronym>
  <official_title>Prospective, Multicenter, Observational Study Evaluate Single-Staged Open Complex Ventral Incisional Hernia Repair Using a Biosynthetic Material for Midline Fascial Closure Reinforcement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, observational study to evaluate performance of GORE® BIO-A® Tissue
      Reinforcement when used to reinforce midline fascial closure in single-staged open complex
      ventral incisional hernia repair.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate the performance of the biosynthetic mesh when used to reinforce the
      midline fascial closure in single-staged open complex ventral incisional hernia repair. It is
      designed to test the null hypothesis that the two year recurrence rate associated with the
      device is greater than or equal to 50% vs the alternative hypothesis that the two year
      recurrence rate is less than 50%.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hernia Recurrence Rate</measure>
    <time_frame>at about 24 months</time_frame>
    <description>Investigator confirmed hernia recurrence by physical examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early and Long-term Complication Rates</measure>
    <time_frame>after surgery (day 1) to 24 months</time_frame>
    <description>Surgical site abdominal wound event rate</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">104</enrollment>
  <condition>Ventral Incisional Hernia</condition>
  <arm_group>
    <arm_group_label>GORE® BIO-A® Tissue Reinforcement</arm_group_label>
    <description>Single-staged open complex ventral incisional repair of primary or recurrent anterior abdominal wall hernia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GORE® BIO-A® Tissue Reinforcement</intervention_name>
    <description>Retrorectus or intraperitoneal placement of device to reinforce the midline fascial closure after single-staged open complex ventral incisional hernia repair of primary or recurrent anterior abdominal wall hernia.</description>
    <arm_group_label>GORE® BIO-A® Tissue Reinforcement</arm_group_label>
    <other_name>Biosynthetic Mesh</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        general and teaching hospitals
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be informed about the study, and will have read; understood and signed
             the informed consent and authorization to use their PHI, as applicable

          -  Subjects willing and able to submit to postoperative follow-up evaluations including
             quality of life assessments up to 24 months after surgery

          -  Subjects of either gender that are at least the age of 18 years

          -  Subjects will have a Body-Mass Index (BMI) of &lt; 40

          -  Subjects will be undergoing single-staged open complex ventral incisional hernia
             repair with the retrorectus or intraperitoneal placement technique of the GORE® BIO-A®
             Tissue Reinforcement

          -  Subjects in which intraoperatively their surgical field/wound is characterized either
             a Type 2 or Type 3 in Table 1 in Section 12.0

          -  Subjects with a hernia defect &gt; 9 cm2 large when measured intraoperatively

          -  Subjects in which the required mobility for midline fascial closure without excessive
             tension to reapproximate the rectus abdominis muscle intraoperatively can be achieved

          -  Subjects in which one unit of GORE® BIO-A® Tissue Reinforcement will adequately
             reinforce the midline fascial closure with at least 4 cm of overlap laterally

        Exclusion Criteria:

          -  Subjects who, in the surgeon's opinion, would have a difficult time comprehending or
             complying with the requirements of the study

          -  Subjects with a BMI &gt; 40

          -  Subjects with evidence of pre-existing systemic infections

          -  Subjects with cirrhosis or are currently being treated with dialysis

          -  Subjects with a wound-healing disorder

          -  Subjects with autoimmune disorder requiring &gt; 10mg of a corticosteroid per day

          -  Subjects who are immunocompromised such as, with HIV or transplant, or receiving chemo
             or radiation therapy

          -  Subjects with a hernia defect &lt; 9 cm2 large when measured intraoperatively

          -  Subjects with a hernia defect requiring more than one unit of GORE® BIO-A® Tissue
             Reinforcement

          -  Subjects in which intraoperatively there is an inability to achieve retrorectus or
             intraperitoneal placement of the device

          -  Subjects in which a midline fascial closure without excessive tension cannot be
             achieved

          -  Subjects in which intraoperatively their surgical field/wound is characterized either
             a Type 1 or Type 4 in the Table 1 in Section 12

          -  Subjects in need of concomitant surgical procedures other than indicated in the
             protocol as acceptable

          -  Subject in which their complex ventral incisional hernia repair requires more than one
             operation to reduce hernia and close fascia, including serial excision procedures -
             requiring subsequent surgery to complete their hernia repair

          -  Subjects with a hernia repair requiring an emergent procedure, such as strangulated
             bowel

          -  Subjects in which intraoperatively untreated cancer was found
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Rosen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Department of Surgery</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Medical Center, Case Western Reserve University, Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canisius-Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <state>The Netherlands</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2011</study_first_submitted>
  <study_first_submitted_qc>March 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2011</study_first_posted>
  <results_first_submitted>April 10, 2015</results_first_submitted>
  <results_first_submitted_qc>November 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 24, 2015</results_first_posted>
  <last_update_submitted>November 18, 2015</last_update_submitted>
  <last_update_submitted_qc>November 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Complex ventral incisional hernia repair</keyword>
  <keyword>reapproximation of the rectus abdominis muscle</keyword>
  <keyword>retrorectus or intraperitoneal placement technique</keyword>
  <keyword>mobility for midline fascial closure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Incisional Hernia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>104 subjects recruited from 9 sites in the US and Netherlands between March 2011 and December 2012</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Single-staged Open Complex Ventral Incisional Hernia Repair</title>
          <description>GORE® BIO-A® Tissue Reinforcement to reinforce the midline fascial closure in single-staged open complex ventral incisional (primary or recurrent anterior abdominal wall) hernia repair.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single-staged Open Complex Ventral Incisional Hernia Repair</title>
          <description>primary or recurrent anterior abdominal wall hernia
GORE BIO-A Tissue Reinforcement: Retrorectus or intraperitoneal placement of device to reinforce the midline fascial closure</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="104"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.7" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Wound Classification</title>
          <description>Intraoperatively assessed, based on the level of contamination present, or due to concomitant surgical procedures, the surgical field was managed to reduce or appropriately eliminate microbial contaminants. After devitalized tissue was removed and the appropriate bioburden reduction techniques completed, the resulting surgical field/wound was characterized and documented as applicable based on the surgical wound classification scheme as suggested by the Centers for Disease Control, US Department of Human Services, with modifications for inclusion of stomas.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Clean-contaminated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contaminated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (Body Mass Index)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hernia Recurrence Rate</title>
        <description>Investigator confirmed hernia recurrence by physical examination</description>
        <time_frame>at about 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single-staged Open Complex Ventral Incisional Hernia Repair</title>
            <description>primary or recurrent anterior abdominal wall hernia
GORE BIO-A Tissue Reinforcement: Retrorectus or intraperitoneal placement of device to reinforce the midline fascial closure</description>
          </group>
        </group_list>
        <measure>
          <title>Hernia Recurrence Rate</title>
          <description>Investigator confirmed hernia recurrence by physical examination</description>
          <units>% of subjects with recurrent hernia</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="11.0" upper_limit="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early and Long-term Complication Rates</title>
        <description>Surgical site abdominal wound event rate</description>
        <time_frame>after surgery (day 1) to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single-staged Open Complex Ventral Incisional Hernia Repair</title>
            <description>primary or recurrent anterior abdominal wall hernia
GORE BIO-A Tissue Reinforcement: Retrorectus or intraperitoneal placement of device to reinforce the midline fascial closure</description>
          </group>
        </group_list>
        <measure>
          <title>Early and Long-term Complication Rates</title>
          <description>Surgical site abdominal wound event rate</description>
          <units>% of subjects with events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>GORE® BIO-A® Tissue Reinforcement</title>
          <description>Retrorectus or intraperitoneal placement of device to reinforce the midline fascial closure after single-staged open complex ventral incisional hernia repair of primary or recurrent anterior abdominal wall hernia.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bowel obstruction related to concomitant small bowel anastomoses during index surgery</sub_title>
                <description>Secondary outcome event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Anastomotic leak related to concomitant bowel resection during index surgery</sub_title>
                <description>Secondary outcome event</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Surgical site seroma</sub_title>
                <description>Secondary outcome event</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Surgical site infection</sub_title>
                <description>Secondary outcome event</description>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Proposed publications/public disclosures within 60 days prior to submission will be provided to sponsor for review by Investigator. Sponsor may make modifications to the proposals only as reasonably necessary to ensure the proper use of any references to itself, its trademarks, and trade names. Sponsor may correct inaccuracies in any technical specifications or descriptions of the biosynthetic material.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lori Norton, PhD</name_or_title>
      <organization>W. L. Gore &amp; Associates, Inc., Sponsor</organization>
      <phone>800-437-8181</phone>
      <email>lnorton@wlgore.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

